LOC: HIV Prevention Trials Network

描述（由申请人提供）：艾滋病毒预防试验网络（HPTN）的使命是进行研究，旨在确定艾滋病毒预防干预措施的最佳组合，以预防艾滋病毒感染的最高风险人群感染艾滋病毒。HPTN将由哥伦比亚大学的Wafaa EI-Sadr博士和Myron S.科恩，北卡罗来纳州大学查佩尔山，并支持经验丰富的运营，实验室和统计和数据中心。艾滋病毒/艾滋病问题小组将处理和支持两个研究优先领域，以实现以下八个具体目标：优先领域1的具体目标：预防艾滋病毒感染的综合战略：目标1：制定预防南部非洲年轻妇女感染艾滋病毒的综合战略;目标2：制定预防男男性行为者感染艾滋病毒的综合战略;次级目标2a：确定一项综合战略，防止美洲未感染艾滋病毒的男男性行为者和变性妇女感染艾滋病毒;次级目标2b：确定一项综合战略，防止美国感染艾滋病毒的男男性行为者传播艾滋病毒（美国）;目标3：制定一项综合战略，预防东欧和亚洲注射毒品使用者感染艾滋病毒;目标4：实施一项综合战略，在撒哈拉以南非洲几乎消除（<1%）不和谐夫妇的艾滋病毒传播;目标5：制定方法，使撒哈拉以南非洲的男男性行为者参与预防研究，为制定预防这一人群感染艾滋病毒的综合战略铺平道路优先领域2的具体目标：暴露前预防：目标6：评价含有马拉韦罗（MVC）的抗逆转录病毒治疗方案对PrEP的疗效;目的7：开发具有良好特征的PrEP新药，包括长效药物;目的8：开发药物统计学模型，以确定PrEP新药的作用。

DESCRIPTION (provided by applicant): The mission of the HIV Prevention Trials Network (HPTN) is to conduct research designed to identify the best combinations of HIV prevention interventions to prevent HIV infection in populations at the highest risk for this infection. The HPTN will be led by Drs. Wafaa EI-Sadr, Columbia University, and Myron S. Cohen, University of North Carolina at Chapel Hill, and supported by experienced operations, laboratory and statistical and data centers. The HPTN will address and support the two research Priority Areas in order to achieve the following eight Specific Aims: Specific Aims for Priority Area 1: Integrate Strategies to Prevent HIV Infection: Aim 1: To develop an integrated strategy to prevent HIV infection in young women in Southern Africa; Aim 2: To develop integrated strategies to prevent HIV infection in men who have sex with men (MSM); Sub-aim 2a: To identify an integrated strategy to prevent HIV acquisition in HIV-uninfected MSM and transgender women in the Americas; Sub-aim 2b: To identify an integrated strategy to prevent HIV transmission from HIV-infected MSM in the United States (U.S.); Aim 3: To develop an integrated strategy to prevent HIV infection in injection drug users (IDUs) in Eastern Europe and Asia; Aim 4: To implement an integrated strategy to virtually eliminate (<1%) HIV transmission in discordant couples in sub-Saharan Africa {SSA}; Aim 5: To develop methods to engage MSM in SSA in prevention research, paving the way for development of an integrated strategy to prevent HIV infection in this population Specific Aims for Priority Area 2: Pre-exposure Prophylaxis {PrEP}: Aim 6: To evaluate the efficacy of an ARV regimen containing maraviroc (MVC) for PrEP; Aim 7: To develop new agents for PrEP with favorable profiles, including long lasting agents; Aim 8: To develop pharmacostatistical models to define the role of new agents for PrEP.